Food and Drug Administration (FDA) stated Monday it licenses a drug from Global Blood Therapeutics to treat sickle cell illness in adults and children 12 years or older.
The treatment will probably be priced at $10,417 per month, or around $125,000 per year, and might be sold under the name Oxbryta. It’s the second drug in recent days to win U.S. license for sickle cell anemia, and the first to focus on the underlying cause of the illness rather than signs.
Last week, Novartis AG’s Adakveo gained U.S. regulatory approval to alleviate the incidence of sickle cell-related pain crises, a common sign of the illness.
GBT’s drug, chemically called voxelotor, works by stopping red blood cells from sickling, a deformation that restricts the flow of oxygen in blood vessels, leading to extreme pain and organ injury.
GBT says that mitigated blood cell sickling will considerably relieve signs in sickle cell sufferers. It’ll monitor patients’ long-interval symptom reduction in a confirmatory study; it’s going to launch by the end of the year.
GBT decided the price of its drug partly on estimates of the annual cost of care for sickle-cell sufferers, which may currently run in excess of $285,000 per year to handle patients’ symptoms, GBT’s CEO, Ted Love, said in an interview.
State Medicaid plans, which cover about half of U.S. sickle cell patients, will obtain discounts that carry the price of the drug down to under $100,000 per year, or around $8,000 monthly, GBT executives said on a Monday conference call.
GBT expects that its drug, Oxbryta, will be utilized in combination with Novartis’s drug, Adakveo, for the portion of sickle cell sufferers who’ve frequent pain crises. Novartis has priced Adakveo between $84,852 and $113,136 per year for many sufferers.